Overview

177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

Status:
Recruiting
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of 177 Lu -labeled PSMA ligand(PSMA-I＆T) in the treatment of mCRPC in Asianethics.
Phase:
Phase 2
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University